SCHEMBL312155

SCHEMBL312155

O=c1cc(-c2ccc(O)cc2)[nH]c2c(O)ccc(O)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.42
MAPT P10636 3/20 0.42
MEN1 O00255 2/20 0.42
CYP3A4 P08684 2/20 0.42
AR P10275 2/20 0.42
HPGD P15428 2/20 0.42
MAPK1 P28482 2/20 0.42
RAF1 P04049 1/20 0.42
CDC7 O00311 1/20 0.41
ADORA2A P29274 1/20 0.41
ADORA2B P29275 1/20 0.41
RIPK1 Q13546 2/20 0.40
CDK4 P11802 1/20 0.39
CCND1 P24385 1/20 0.39
CDK5 Q00535 3/20 0.39
CDK5R1 Q15078 3/20 0.39
PKM P14618 3/20 0.39
CCNB2 O95067 2/20 0.39
CDK1 P06493 2/20 0.39
CCNB1 P14635 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL312037 0.78 HPGD (0.50) KMT2AMAPTMEN1CYP3A4AR
SCHEMBL312031 0.78 TERT (0.49) KMT2AMEN1CYP3A4HPGDMAPK1
SCHEMBL312027 0.78 KDM4E (0.55) KMT2AHPGDCYP1A1CYP1B1KDM4E
SCHEMBL311827 0.78 ADORA2A (0.39) KMT2AMEN1CDC7ADORA2AADORA2B
SCHEMBL311542 0.78 KMT2A (0.42) KMT2AMEN1HPGDMAPK1CDC7
SCHEMBL311728 0.75 ESR1 (0.49) KMT2AMAPTMEN1CYP3A4AR
SCHEMBL311852 0.70 KDM4E (0.51) KMT2AMAPTMEN1HPGDMAPK1
SCHEMBL31552890 0.70 KDM4E (0.51) KMT2AMAPTMEN1HPGDMAPK1
SCHEMBL313992 0.69 SMN1; SMN2 (0.43) KMT2AMEN1HPGDMAPK1CDC7
SCHEMBL312015 0.69 MEN1 (0.46) KMT2AMEN1HPGDMAPK1CDC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242130-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-08-14 US disclosed
EP-1838296-B1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP (CA) 2012-08-08 EP disclosed
US-8093273-B2 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-01-10 US disclosed
EP-2332527-A2 Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2011-06-15 EP disclosed
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2009-10-15 US disclosed
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases HEPALINK (HONG KONG) LIMITED (HK) 2006-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205767-A1 Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases APOB, APOL1, FABP3 KMT2A 2842/4885MAPT 2914/4885MEN1 4653/4885
US-20090259048-A1 FLAVANOIDS AND ISOFLAVANOIDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES APOB, APOL1, FABP3 KMT2A 2842/4885MAPT 2914/4885MEN1 4653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.